Results 141 to 150 of about 6,314 (165)

Targeting SIRT1: A Potential Strategy for Combating Severe COVID-19. [PDF]

Biomed Res Int
Shokri-Afra H, Saber Jeyvan F, Barartabar Z, Khanicheragh P, Yousefi Abdolmaleki E, Ilbeigi D, Musavi H, Malekzadegan Y.   +7 more
europepmc   +1 more source

SARS-CoV-2 ORF3a drives dynamic dense body formation for optimal viral infectivity. [PDF]

Nat Commun
Hartmann S, Radochonski L, Ye C, Martinez-Sobrido L, Chen J.   +4 more
europepmc   +1 more source

SARS-CoV-2 Nsp1 Is a Major Suppressor of HLA Class I and Class II Expression. [PDF]

Viruses
Schirmeister I, Eckert N, Weigang S, Fuchs J, Kern L, Kochs G, Halenius A.   +6 more
europepmc   +1 more source

HOPS disruption impairs APP trafficking and processing, promoting exosomal secretion of APP-CTFs

Draper D, George AE, Veenendaal T, Dijk Sv, Verweij FJ, Klumperman J, Farías GG.   +6 more
europepmc   +1 more source

SARS-Cov-2 ORF3a: Mutability and function

International Journal of Biological Macromolecules, 2021
In this study, analysis of changes of SARS-CoV-2 ORF3a protein during pandemic is reported. ORF3a, a conserved coronavirus protein, is involved in virus replication and release. A set of 70,752 high-quality SARS-CoV-2 genomes available in GISAID databank
Martina Bianchi, Alessandra Borsetti, Stefano Pascarella   +2 more
exaly   +5 more sources

ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress [PDF]

Developmental Cell, 2021
Viral entry and egress are important determinants of virus infectivity and pathogenicity. β-coronaviruses, including the COVID-19 virus SARS-CoV-2 and mouse hepatitis virus (MHV), exploit the lysosomal exocytosis pathway for egress. Here, we show that SARS-CoV-2 ORF3a, but not SARS-CoV ORF3a, promotes lysosomal exocytosis.
Hong Zhang, Hongyu Deng, Mingming Ji
exaly   +3 more sources

Exploring polyamine interactions and binding pockets in SARS-CoV-2 ORF3a

Journal of Molecular Graphics and Modelling, 2023
Ongoing global pandemic caused by coronavirus (COVID-19) requires urgent development of vaccines, treatments, and diagnostic tools. Open reading frame 3a (ORF3a) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered to be a potential drug target for COVID-19 treatment.
Pornthep Sompornpisut, Panisak Boonamnaj   +1 more
exaly   +3 more sources

SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway

Virology, 2022
Heightened inflammatory response is a prominent feature of severe COVID-19 disease. We report that the SARS-CoV-2 ORF3a viroporin activates the NLRP3 inflammasome, the most promiscuous of known inflammasomes. Ectopically expressed ORF3a triggers IL-1β expression via NFκB, thus priming the inflammasome.
Michael McIntosh, Julia Loeb, Ibukun A Akinyemi   +2 more
exaly   +3 more sources